Company: RGBP
Filing Date: 2025-12-05
Form Type: 253G1
Source: 0001493152-25-026350
Chunk: 134

Company: Regen BioPharma Inc
Filing Date: 2025-12-05
Form: 253G1
Chunk 134
---
ishment Convertible Debt            |     |                          |         - |   |     |      |     1,150 |   |
| Total other income (expense), net                         |     |                          |  (251,034 | ) |     |      | 1,843,456 |   |
| Net loss before income taxes                              |     |                          |  (668,255 | ) |     |      | 1,156,507 |   |
| Income tax provision                                      |     |                          |         - |   |     |      |         - |   |
| Net loss                                                  |     | $                        |  (668,255 | ) |     | $    | 1,156,507 |   |
| Net income (loss) attributable to common shareholders     |     | $                        |  (668,255 | ) |     | $    | 1,023,508 |   |
| Per common share basic and diluted:                       |     |                          |           |   |     |      |           |   |
| Net loss per common share attributable to Regen Biopharma 
 shareholders, basic and diluted                           |     | $                        |     (0.16 | ) |     | $    |      0.29 |   |
| Number of weighted average shares - basic and diluted     |     |                          | 4,110,265 |   |     |      | 3,536,963 |   |

The Accompanying Notes are an Integral Part of These Financial Statements

All stock amounts have been retroactively adjusted
to reflect a 1 for 1500 reverse stock split of all issued series of stock effective as of March 6, 2023

<div align='center'>102

REGEN BIOPHARMA , INC.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS )</div>

|                                       |     | Year ended September 30 
 2024                    |          |   |     | 2023 |           |
|:--------------------------------------|:----|:------------------------|:---------|:--|:----|:-----|----------:|
| Net Income ( Loss)                    |     | $                       | (668,255 | ) |     | $    | 1,156,507 |
| Other Comprehensive Loss:             |     |                         |          |   |     |      |           |
| Unrealized Loss Investment Securities |     |                         | (204,847